European Commission allows Glycom A/S to place lacto-N-tetraose (‘LNT’), obtained by microbial fermentation with a genetically modified strain of Escherichia coli, strain K12 DH1, on the Union market as a novel food. CLICK HERE Tags: HMO, LNT, novel food Read more articles Previous PostFermented Food Consumption Associated with Changes in the Gut Microbiome Next PostThe Global Prebiotic Association Welcomes FrieslandCampina Ingredients as a New Member You Might Also Like Type 3 resistant starch from Canna edulis modulates obesity and low grade inflammation in mice November 24, 2021 Australian Trial Examines Impact of HAMSAB (Resistant Starch-based) Prebiotic and Patients with High Blood Pressure January 11, 2023 Active Vitamin D Levels Linked to Gut Microbiome November 26, 2020
Type 3 resistant starch from Canna edulis modulates obesity and low grade inflammation in mice November 24, 2021
Australian Trial Examines Impact of HAMSAB (Resistant Starch-based) Prebiotic and Patients with High Blood Pressure January 11, 2023